#1 Clinical Trials Search in Europe

Ads-011

A groundbreaking clinical trial is underway to evaluate the safety and effectiveness of ARO-C3, also known as ADS-011, in treating complement-mediated kidney disease. This Phase 1/2a study aims to assess the drug’s safety, tolerability, and how it behaves in the body of adult patients with this condition. The trial represents a significant step forward in developing new treatments for patients with complement-mediated renal disorders.

Table of Contents

What is ADS-011?

ADS-011 is a new medication being developed to treat certain kidney diseases. It’s also known by its product name ARO-C3[1]. This drug is a type of medication called a small interfering RNA (siRNA), which is a synthetic molecule designed to interfere with specific processes in the body[1].

How Does ADS-011 Work?

ADS-011 works by targeting a part of the immune system called the complement system. Specifically, it aims to reduce the levels of a protein called complement component 3 (C3)[1]. In some kidney diseases, the complement system becomes overactive and damages the kidneys. By lowering C3 levels, ADS-011 may help reduce this damage and improve kidney function.

What Conditions Does ADS-011 Treat?

ADS-011 is being developed to treat complement-mediated kidney diseases. These are a group of rare kidney disorders where the complement system attacks and damages the kidneys. Two specific conditions being studied are:

  • C3 Glomerulopathy (C3G): A rare kidney disease where deposits of C3 build up in the kidneys, causing damage[1].
  • IgA Nephropathy (IgAN): A kidney disease where antibodies called IgA build up in the kidneys, often along with C3 deposits[1].

Current Research on ADS-011

ADS-011 is currently being studied in a clinical trial. This trial is designed to:

  1. Evaluate the safety of ADS-011
  2. Determine how well the body tolerates the medication
  3. Study how the drug moves through the body (pharmacokinetics or PK)
  4. Examine how the drug affects the body (pharmacodynamics or PD)[1]

The main goal of this study is to see if ADS-011 is safe and how it affects C3 levels in people with complement-mediated kidney diseases[1].

Eligibility for the Study

To participate in this study, patients must meet certain criteria. Some key requirements include:

  • Age 18 to 70 years
  • Diagnosed with C3G or IgAN (confirmed by kidney biopsy)
  • Have significant protein in the urine (>750 mg/day)
  • Have kidney function above a certain level (eGFR ≥30 mL/min/1.73m2)
  • Not currently on dialysis
  • Vaccinated against certain bacterial infections or willing to be vaccinated[1]

There are also several conditions that would prevent someone from participating in the study, such as certain other medical conditions or recent use of specific medications[1].

Safety Considerations

As with any new medication, safety is a top priority in this study. The researchers will be closely monitoring for any side effects or adverse reactions. Some specific safety measures include:

  • Regular check-ups and blood tests
  • Monitoring for infections
  • Checking heart function
  • Ensuring participants are vaccinated against certain bacterial infections[1]

It’s important to note that ADS-011 is still in the research phase. While it shows promise, more studies are needed to fully understand its effectiveness and safety for treating complement-mediated kidney diseases.

Aspect Details
Drug Name ARO-C3 (ADS-011)
Drug Type Synthetic, double-stranded, small interfering RNA (siRNA)
Administration Subcutaneous injection
Target Condition Complement-mediated renal disease (C3G and IgAN)
Study Phase Phase 1/2a
Primary Endpoint Incidence, frequency, and severity of treatment-emergent adverse events
Key Inclusion Criteria Adults 18-70 years, confirmed C3G or IgAN diagnosis, significant proteinuria, stable renal function
Key Exclusion Criteria HIV infection, severe kidney damage, recent major surgery, use of certain complement inhibitors

FAQ

  • What is ARO-C3 (ADS-011)? ARO-C3 (ADS-011) is a synthetic, double-stranded, small interfering RNA (siRNA) drug designed to target complement component 3 (C3), which plays a role in complement-mediated kidney diseases.
  • What is the main goal of this clinical trial? The main objective is to evaluate the safety, tolerability, pharmacokinetics (how the drug moves through the body), and pharmacodynamics (how the drug affects the body) of multiple doses of ARO-C3 in subjects with complement-mediated renal disease.
  • Who can participate in this trial? The trial is open to adults aged 18 to 70 with complement-mediated kidney disease, including C3 glomerulopathy (C3G) or IgA nephropathy (IgAN) with C3 presence. Participants must have ongoing disease with significant proteinuria and meet other specific eligibility criteria.
  • How is the drug administered? ARO-C3 is administered through subcutaneous injection, which means it is injected just under the skin.
  • What are some of the key exclusion criteria for this trial? Some key exclusion criteria include HIV infection, severe kidney damage, recent major surgery, use of certain complement inhibitors, history of recurrent infections, uncontrolled hypertension, and recent use of other investigational drugs.

Ongoing Clinical Trials on Ads-011

  • Study on the Safety and Effects of ARO-C3 for Adults with Complement-Mediated Kidney Disease

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Germany

Glossary

  • Complement-mediated renal disease: A group of kidney disorders caused by abnormal activation of the complement system, which is part of the body's immune defense.
  • C3 glomerulopathy (C3G): A rare kidney disease characterized by the buildup of C3 protein in the kidneys, leading to inflammation and damage.
  • IgA nephropathy (IgAN): A kidney disease where antibodies called IgA build up in the kidneys, causing inflammation and damage over time.
  • Proteinuria: The presence of excess protein in the urine, which can be a sign of kidney damage.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Pharmacodynamics (PD): The study of how a drug affects the body, including its mechanism of action and relationship between drug concentration and effect.
  • siRNA: Small interfering RNA, a type of molecule that can be used to 'silence' specific genes and potentially treat diseases.
  • Subcutaneous injection: A method of administering medication by injecting it into the layer of tissue just beneath the skin.
  • Glomerular filtration rate (GFR): A measure of how well the kidneys are filtering waste from the blood.
  • Complement system: A part of the immune system that enhances the body's ability to clear microbes and damaged cells, but can also contribute to certain diseases when overactive.

References

  1. http://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-aro-c3-for-adults-with-complement-mediated-kidney-disease/